News
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
REMINDER: Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate Updates
Jaguar Health, Inc. to conduct investor webcast on May 14, 2024 at 8:30 a.m. Eastern to review first-quarter 2024 financials and provide corporate updates. Company plans to file its Earnings Report on the same day -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Announces Submission of Clinical Trial Applications for Crofelemer for the Rare Disease Indications Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome (SBS) in Europe
Jaguar Health's crofelemer granted Orphan Drug Designation by FDA and EMA for MVID and SBS. Clinical trials submitted in Italy and Germany for SBS and MVID treatment. Jaguar focuses on plant-based medicines for gastrointestinal distress -
-
